Ranjana H Advani1, Fangxin Hong2, Richard I Fisher2, Nancy L Bartlett2, K Sue Robinson2, Randy D Gascoyne2, Henry Wagner2, Patrick J Stiff2, Bruce D Cheson2, Douglas A Stewart2, Leo I Gordon2, Brad S Kahl2, Jonathan W Friedberg2, Kristie A Blum2, Thomas M Habermann2, Joseph M Tuscano2, Richard T Hoppe2, Sandra J Horning2. 1. Ranjana H. Advani, Richard T. Hoppe, and Sandra J. Horning, Stanford University, Stanford; Joseph M. Tuscano, University of California, Davis Cancer Center, Sacramento, CA; Fangxin Hong, Dana-Farber Cancer Institute, Boston, MA; Richard I. Fisher and Jonathan W. Friedberg, University of Rochester, Rochester, NY; Nancy L. Bartlett, Washington University School of Medicine, St Louis, MO; K. Sue Robinson, Queen Elizabeth II Health Science Center, Halifax, Nova Scotia; Randy D. Gascoyne, British Columbia Cancer Agency, Vancouver, British Columbia; Douglas A. Stewart, Tim Baker Cancer Institute, Calgary, Alberta, Canada; Henry Wagner Jr, Penn State Cancer Institute, Hershey, PA; Patrick J. Stiff, Loyola University Medical Center, Maywood; Leo I. Gordon, Northwestern University, Chicago, IL; Bruce D. Cheson, Georgetown University Hospital, Washington, DC; Brad S. Kahl, University of Wisconsin, Madison, WI; Kristie A. Blum, Ohio State University, Columbus, OH; and Thomas M. Habermann, Mayo Clinic, Rochester, MN. radvani@stanford.edu. 2. Ranjana H. Advani, Richard T. Hoppe, and Sandra J. Horning, Stanford University, Stanford; Joseph M. Tuscano, University of California, Davis Cancer Center, Sacramento, CA; Fangxin Hong, Dana-Farber Cancer Institute, Boston, MA; Richard I. Fisher and Jonathan W. Friedberg, University of Rochester, Rochester, NY; Nancy L. Bartlett, Washington University School of Medicine, St Louis, MO; K. Sue Robinson, Queen Elizabeth II Health Science Center, Halifax, Nova Scotia; Randy D. Gascoyne, British Columbia Cancer Agency, Vancouver, British Columbia; Douglas A. Stewart, Tim Baker Cancer Institute, Calgary, Alberta, Canada; Henry Wagner Jr, Penn State Cancer Institute, Hershey, PA; Patrick J. Stiff, Loyola University Medical Center, Maywood; Leo I. Gordon, Northwestern University, Chicago, IL; Bruce D. Cheson, Georgetown University Hospital, Washington, DC; Brad S. Kahl, University of Wisconsin, Madison, WI; Kristie A. Blum, Ohio State University, Columbus, OH; and Thomas M. Habermann, Mayo Clinic, Rochester, MN.
Abstract
PURPOSE: The phase III North American Intergroup E2496 Trial (Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma) compared doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) with mechlorethamine, doxorubicin, vincristine, bleomycin, vinblastine, etoposide, and prednisone (Stanford V). We report results of a planned subgroup analysis in patients with stage I or II bulky mediastinal Hodgkin lymphoma (HL). PATIENTS AND METHODS: Patients were randomly assigned to six to eight cycles of ABVD every 28 days or Stanford V once per week for 12 weeks. Two to 3 weeks after completion of chemotherapy, all patients received 36 Gy of modified involved field radiotherapy (IFRT) to the mediastinum, hila, and supraclavicular regions. Patients on the Stanford V arm received IFRT to additional sites ≥ 5 cm at diagnosis. Primary end points were failure-free survival (FFS) and overall survival (OS). RESULTS: Of 794 eligible patients, 264 had stage I or II bulky disease, 135 received ABVD, and 129 received Stanford V. Patient characteristics were matched. The overall response rate was 83% with ABVD and 88% with Stanford V. At a median follow-up of 6.5 years, the study excluded a difference of more than 21% in 5-year FFS and more than 16% in 5-year OS between ABVD and Stanford V (5-year FFS: 85% v 79%; HR, 0.68; 95% CI, 0.37 to 1.25; P = .22; 5-year OS: 96% v 92%; HR, 0.49; 95% CI, 0.16 to 1.47; P = .19). In-field relapses occurred in < 10% of the patients in each arm. CONCLUSION: For patients with stage I or II bulky mediastinal HL, no substantial statistically significant differences were detected between the two regimens, although power was limited. To the best of our knowledge, this is the first prospective trial reporting outcomes specific to this subgroup, and it sets a benchmark for comparison of ongoing and future studies.
RCT Entities:
PURPOSE: The phase III North American Intergroup E2496 Trial (Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma) compared doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) with mechlorethamine, doxorubicin, vincristine, bleomycin, vinblastine, etoposide, and prednisone (Stanford V). We report results of a planned subgroup analysis in patients with stage I or II bulky mediastinal Hodgkin lymphoma (HL). PATIENTS AND METHODS: Patients were randomly assigned to six to eight cycles of ABVD every 28 days or Stanford V once per week for 12 weeks. Two to 3 weeks after completion of chemotherapy, all patients received 36 Gy of modified involved field radiotherapy (IFRT) to the mediastinum, hila, and supraclavicular regions. Patients on the Stanford V arm received IFRT to additional sites ≥ 5 cm at diagnosis. Primary end points were failure-free survival (FFS) and overall survival (OS). RESULTS: Of 794 eligible patients, 264 had stage I or II bulky disease, 135 received ABVD, and 129 received Stanford V. Patient characteristics were matched. The overall response rate was 83% with ABVD and 88% with Stanford V. At a median follow-up of 6.5 years, the study excluded a difference of more than 21% in 5-year FFS and more than 16% in 5-year OS between ABVD and Stanford V (5-year FFS: 85% v 79%; HR, 0.68; 95% CI, 0.37 to 1.25; P = .22; 5-year OS: 96% v 92%; HR, 0.49; 95% CI, 0.16 to 1.47; P = .19). In-field relapses occurred in < 10% of the patients in each arm. CONCLUSION: For patients with stage I or II bulky mediastinal HL, no substantial statistically significant differences were detected between the two regimens, although power was limited. To the best of our knowledge, this is the first prospective trial reporting outcomes specific to this subgroup, and it sets a benchmark for comparison of ongoing and future studies.
Authors: V Bonfante; A Santoro; S Viviani; R Zucali; L Devizzi; M Zanini; J D Tesoro Tess; P Valagussa; A Banfi; G Bonadonna Journal: Eur J Cancer Date: 1992 Impact factor: 9.162
Authors: Bastian von Tresckow; Annette Plütschow; Michael Fuchs; Beate Klimm; Jana Markova; Andreas Lohri; Zdenek Kral; Richard Greil; Max S Topp; Julia Meissner; Josée M Zijlstra; Martin Soekler; Harald Stein; Hans T Eich; Rolf P Mueller; Volker Diehl; Peter Borchmann; Andreas Engert Journal: J Clin Oncol Date: 2012-01-23 Impact factor: 44.544
Authors: T A Lister; D Crowther; S B Sutcliffe; E Glatstein; G P Canellos; R C Young; S A Rosenberg; C A Coltman; M Tubiana Journal: J Clin Oncol Date: 1989-11 Impact factor: 44.544
Authors: Michael Zach Koontz; Sandra J Horning; Raymond Balise; Peter L Greenberg; Saul A Rosenberg; Richard T Hoppe; Ranjana H Advani Journal: J Clin Oncol Date: 2013-01-07 Impact factor: 44.544
Authors: Ranjana H Advani; Richard T Hoppe; Lauren S Maeda; David M Baer; Joseph Mason; Saul A Rosenberg; Sandra J Horning Journal: Int J Radiat Oncol Biol Phys Date: 2010-10-08 Impact factor: 7.038
Authors: Peter Borchmann; Heinz Haverkamp; Volker Diehl; Thomas Cerny; Jana Markova; Anthony D Ho; Hans-Theodor Eich; Hans Konrad Mueller-Hermelink; Lothar Kanz; Richard Greil; Andreas Rank; Ursula Paulus; Lenka Smardova; Christoph Huber; Bernd Dörken; Christoph Nerl; Stefan W Krause; Rolf-Peter Mueller; Michael Fuchs; Andreas Engert Journal: J Clin Oncol Date: 2011-10-11 Impact factor: 44.544
Authors: Volker Diehl; Jeremy Franklin; Michael Pfreundschuh; Bernd Lathan; Ursula Paulus; Dirk Hasenclever; Hans Tesch; Richard Herrmann; Bernd Dörken; Hans-Konrad Müller-Hermelink; Eckhardt Dühmke; Markus Loeffler Journal: N Engl J Med Date: 2003-06-12 Impact factor: 91.245
Authors: Anita Kumar; Carla Casulo; Joachim Yahalom; Heiko Schöder; Paul M Barr; Philip Caron; April Chiu; Louis S Constine; Pamela Drullinsky; Jonathan W Friedberg; John F Gerecitano; Audrey Hamilton; Paul A Hamlin; Steven M Horwitz; Alexandra G Jacob; Matthew J Matasar; Gianna N McArthur; Susan J McCall; Alison J Moskowitz; Ariela Noy; Maria L Palomba; Carol S Portlock; David J Straus; Nicholas VanderEls; Stephanie L Verwys; Joanna Yang; Anas Younes; Andrew D Zelenetz; Zhigang Zhang; Craig H Moskowitz Journal: Blood Date: 2016-07-25 Impact factor: 22.113
Authors: Margaretha G M Roemer; Ranjana H Advani; Azra H Ligon; Yasodha Natkunam; Robert A Redd; Heather Homer; Courtney F Connelly; Heather H Sun; Sarah E Daadi; Gordon J Freeman; Philippe Armand; Bjoern Chapuy; Daphne de Jong; Richard T Hoppe; Donna S Neuberg; Scott J Rodig; Margaret A Shipp Journal: J Clin Oncol Date: 2016-04-11 Impact factor: 44.544
Authors: Ryan C Lynch; Vandana Sundaram; Manisha Desai; Solomon Henry; Douglas Wood; Sarah Daadi; Richard T Hoppe; Ranjana Advani Journal: JCO Oncol Pract Date: 2020-05-05
Authors: Bradford S Hoppe; Raymond B Mailhot Vega; Nancy P Mendenhall; Eric S Sandler; William B Slayton; Howard Katzenstein; Michael J Joyce; Zuofeng Li; Stella Flampouri Journal: Int J Part Ther Date: 2020-04-27
Authors: Matthew D Hall; Stephanie A Terezakis; John T Lucas; Eve Gallop-Evans; Karin Dieckmann; Louis S Constine; David Hodgson; Jamie E Flerlage; Monika L Metzger; Bradford S Hoppe Journal: Int J Radiat Oncol Biol Phys Date: 2021-08-12 Impact factor: 7.038
Authors: Thomas M Habermann; Arushi Khurana; Ruth Lentz; John J Schmitz; Alexander G von Bormann; Jason R Young; Christopher H Hunt; Sara N Christofferson; Grzegorz S Nowakowski; Kristen B McCullough; Pedro Horna; Adam J Wood; William R Macon; Paul J Kurtin; Scott C Lester; Scott L Stafford; Ushrasree Chamarthy; Faraz Khan; Stephen M Ansell; Rebecca L King Journal: Leuk Lymphoma Date: 2020-09-23